• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Syngene

    Aphena Pharma Solutions

    Alcami

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Flow Sciences

    Reed-Lane

    Aphena Pharma Solutions

    Alcami

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    CMOs Are Willing to Pay for More Innovation

    Downstream improvements top the list

    Related CONTENT
    • A Potential “Marriage”
    • Injectables Firms Expand Capacity
    • TFF Expands Engagement with Experic
    • India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    • The Pandemic’s Become an Insurmountable Opportunity
    Eric S. Langer, BioPlan Associates09.11.15
    Contract manufacturing organizations (CMOs) have long been at the forefront of new technology adoption as they seek to improve processes and efficiencies in their multi-product facilities. Results from our industry study, the 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1, support CMOs’ role at the leading edge of innovation, demonstrating that CMOs outpace biotherapeutic developers in their consideration and uptake of new products and technologies.

    In the case of downstream processing (DSP) and purification, though, there may be more demand than innovation. Purification continues to be a pressing issue for CMOs today, as a worrying 64% of CMOs surveyed reported experiencing serious (27%) or some (37%) bottleneck problems at their facility as a result of downstream processing. CMOs responding to our study were 50% more likely than biotherapeutic developer respondents to report big bottlenecks at their facilities.

    Faced with significant operational problems, it’s not surprising that CMOs are pushing for downstream advances, often at a higher rate than biotherapeutic developers. Some 45% of CMOs surveyed reported that the most important area to address to avoid future capacity constraints is to develop better downstream purification technologies. CMOs also see the potential for single-use products to head off future capacity issues, and to note that more cost-effective and better-performing single-use products are needed. 

    To dive further into CMOs demand for downstream innovation and their technology adoption, we evaluated perceptions of the current DSP solutions the industry is considering this year. We found over two-dozen viable alternatives being investigated by CMOs and biotherapeutic developers this year. Figure 1 shows the top set of technologies, and their rate of evaluation over the past six years. We also found that each of these is being evaluated significantly more frequently as candidates by CMOs than biotherapeutic developers. For example:
    • Use of filters instead of resin chromatography: 72.7% of CMOs considering versus 26.2% of developers;
    • Use of high capacity resins: 63.6% of CMOs vs. 47.7% of developers;
    • In-line buffer dilution systems: 54.5% vs. 47.7%;
    • Single-use pre-packed columns: 54.5% vs. 33.8%.
    We also noted that biotherapeutic developers topped CMOs in expressed interest in areas like continuous purification systems and on-line analytical and control devices. In other words, the most popular technologies are being evaluated to a greater degree by CMOs than by biodevelopers.

    Chromatography, single-use products in the crosshairs
    The leading downstream operational area in need of better products, as noted by CMOs—use of filters instead of resin chromatography—is in fact at its highest point in at least 5 years, based on our analysis of previous reports. The biomanufacturing industry clearly has problems with chromatography steps, which are blamed for constraints more than ultrafiltration steps or depth filtration.

    CMOs’ desire for innovation in this area is supported by separate results from our study. Indeed, when we surveyed the industry on the 5 new product development areas they would most like suppliers to focus on—not just downstream—we discovered that among CMOs the top 2 were:
    • Disposable purification products: 47.8% vs. 33.8% of developers; and
    • Chromatography products: 43.5% vs. 34.5% of developers.
    CMOs interests have tended to be a leading edge indicator of future adoption, so it is likely that these areas will see broader demand for new and better products in the future, as well.

    In other areas of our study, we found that alternatives to Protein A resins continue to be less implemented with suitable alternatives scarce. This year, asked what their organizations had implemented to improve downstream purification operations at their facility within the past year, only 1 in 12 (8.3%) of CMOs said that they had switched to alternatives to Protein A. That figure was down from 18.2% in 2014. Interest in alternatives, however, has certainly not waned: This year, half of our CMO respondents reported having investigated Protein A alternatives, almost three times the percentage from last year. What this suggests—more investigating, fewer switching—is that the right alternatives have not yet presented themselves to CMOs, despite their continued interest.

    Disposable purification devices
    Meanwhile, the appearance of disposable purification products at the top of the innovation list for CMOs is to be expected, given the positive experiences CMOs report having with other single use devices. Indeed, three-quarters of CMO respondents reported investigating single-use, disposable downstream technologies could improve their downstream purification operations. CMOs were more likely to credit disposable products with operational improvements than a variety of other implementations, including downstream process optimization, and use of membrane-based filtration technologies.

    Furthermore, when asked how CMOs improved their biomanufacturing performance overall last year—not just downstream—CMOs were most likely to point to the use of disposable/single-use devices, ahead of developer favorites such as overall better control of processes and better analytical testing and product release services. That result may also represent CMOs’ greater adoption of single-use devices. In fact, among disposables users, more than 8 in 10 CMOs report not unexpectedly using a greater variety of single-use products including disposable filter cartridges, buffer containers, depth filters, tangential flow filtration devices and pre-assembled tubing kids, among others.

    It’s worth noting that of the 15 disposable applications we measured, penetration was lowest among CMOs for disposable chromatography devices. Again, not unexpected, given the lack of such devices currently commercially available.

    Analytical assays: An emerging CMO priority
    Beyond the need for better downstream and single-use equipment—disposable probes and sensors, bags and connectors—another area CMOs are expressing interest in is analytical assays. Such assays include a wide range of testing including those used routinely for QA/QC, but also far beyond, to determine and document critical aspects of the active agent/API and finished product. Even the complex characterization of biomolecules for the development of biosimilars is creating greater demand. This also appears to be a growing priority for CMOs. Looking back over recent years, this year’s 30.4% expressing interest in assay innovation is up from last year’s 11.1%. Assays, particularly including bioassays, whether in vitro or in vivo, are an area where few bioprocessing professionals and facilities have developed the needed knowledge and expertise.

    Faced by a lack of in-house expertise, biomanufacturers have taken to outsourcing a greater percentage of bioassays in recent years. In this year’s study, analytical testing of bioassays was the most commonly outsourced biomanufacturing activity, outsourced to some degree by 86.3% of respondents, up from 61.4% in 2010. What’s more, industry demand for outsourced analytical testing is unlikely to abate: More than 4 in 10 respondents said they expect to outsource bioassay testing at “significantly” higher levels in the next 2 years. To put that in context, only 1 in 5 said the same about fill/finish operations, which was next on the list for outsourcing increases.

    As such, CMO interest in assay innovation may well be related to the uptick in demand for their services, both current and forecast. While we didn’t break down the assay areas most urgently in need of new or improved testing methods by CMO versus biodeveloper respondents, our analysis indicates that, industry-wide, advances are sought particularly in:
    • Bio-assays to assess potency for release of drugs: 43.2%;
    • Biotech drug comparability for in-house manufacturing changes as well as biosimilars: 35.5%; and
    • Host cell protein assays: 33.5%.
    A number of other areas were identified such as aggregation, in-process testing methods, etc. CMOs’ desire for assay innovation may also be related to the advent of biosimilars, which are expected to provide a boost in business for these organizations. Besides the need to assess and document product composition and quality, improved assays and analytical capabilities are necessary for biosimilars, not only to prove similarity but also to ascertain the differences between products. Between increased demand for outsourced assay testing services and the coming wave of biosimilars that require comparability testing, CMOs are likely to continue to seek out improved analytical assays in the years to come. 

    Conclusion
    Novel technologies remains top of mind for CMOs again this year, and with the exception of assays, new technology adoption is often tied to disposable applications and downstream purification.

    Our study results also suggest that CMOs aren’t shy about spending on new technologies that can improve efficiencies. Indeed, this year, more than 6 in 10 reported increasing their budgets for new technologies that improve efficiencies/costs for both upstream and downstream production. When we averaged out planned spending, we discovered that:
    • CMOs expected to increase their spending on new technologies to improve efficiencies/costs for upstream production by 7%, compared to 4.1% for survey respondents overall; and
    • CMOs plan to spend 6.1% more on new technologies to improve downstream efficiencies/costs compared to a 5.2% hike for the industry as a whole.
    It’s interesting to see that unlike the industry as a whole, CMOs plan a greater lift in budgets for upstream than downstream innovation. That’s somewhat surprising given the level of challenges CMOs say they are facing in downstream processing.

    This may signal a willingness to spend on downstream innovation but a recognition that the areas in which CMOs most want innovation don’t yet have suitable alternatives. Essentially, disposable alternatives to Protein A resins, for which CMOs are on the lookout, have yet to capture significant market share and/or provide significant cost savings. So while CMOs are looking to increase their downstream innovation budgets, they may be holding back bigger increases for more appealing technologies that better meet their needs. CMOs this year are focusing heavily on the implementation and integration of single-use devices, per our study results, suggesting that this is a key factor they need to take into account when investigating novel technologies.

    It’s also worth remembering that innovation is not only a way for CMOs to improve efficiencies and reduce costs, but also a potential differentiator when looking to win business. As the outsourcing market grows, globalizes and features new entrants including product companies looking to put unused capacity to work, sophisticated technologies and an innovative mindset might well prove to be competitive differentiators for CMOs. 

    References
    1. 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD, April 2015.


    Eric S. Langer
    BioPlan Associates

    is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing,” and many other industry reports. elanger@bioplanassociates.com; 301-921-5979; www.bioplanassociates.com
    Related Searches
    • Development
    • CMO
    • Manufacturing
    • API
    Suggested For You
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    TFF Expands Engagement with Experic TFF Expands Engagement with Experic
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Embedding your Drug Strategy Within a Solid Foundation for Success Embedding your Drug Strategy Within a Solid Foundation for Success
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    PBOA Praises Action On FDA Reauthorization  PBOA Praises Action On FDA Reauthorization
    Adents, Microsoft Present Serialization Solution Adents, Microsoft Present Serialization Solution
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Contract Manufacturing in the Supplement Industry Contract Manufacturing in the Supplement Industry
    Year-End Trends in Biopharma Contract Manufacturing Year-End Trends in Biopharma Contract Manufacturing
    Economics of In-House  Buffer Preparation Economics of In-House Buffer Preparation
    Top 15 Trends in Biopharmaceutical Manufacturing Top 15 Trends in Biopharmaceutical Manufacturing

    Related Columns

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17


    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16


    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16

    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15


    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15

    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login